Where can I find news about HLBBF?

The latest headlines, third-party analysis, and SEC filings for H. Lundbeck A/S (HLBBF) are listed on this page. Headlines come from across the financial press; filings come directly from SEC EDGAR.

Where are HLBBF's SEC filings?

H. Lundbeck A/S (HLBBF)'s 10-K (annual report), 10-Q (quarterly report), 8-K (current report), and proxy filings are listed in the SEC Filings section on this page with direct links to the official EDGAR copies.

Where are HLBBF's earnings call transcripts?

Full earnings call transcripts for H. Lundbeck A/S (HLBBF) — prepared remarks plus speaker-by-speaker analyst Q&A — live on the Earnings tab, alongside the Earnings Reports section that links each quarter's press release and SEC report.

HLBBF

H. Lundbeck A/S

OTC·Drug Manufacturers, Specialty & Generic · Healthcare

$6.64$0.00+0.00%

After hours·$6.64+0.00%

Market cap$5.27B·Market closed·Aug 26 8:00 PM UTC

News & Analysis

H. Lundbeck A/S (HLBBF) Q2 2026 Earnings Call Transcript
H. Lundbeck A/S (HLBBF) Q2 2026 Earnings Call Transcript
seekingalpha.comAug 19, 2026 · 5:31 PM
H. Lundbeck A/S (HLBBF) Discusses PROCEED Trial Results and Data Presented at AHS on Bokunebart for Headache Treatment Transcript
H. Lundbeck A/S (HLBBF) Discusses PROCEED Trial Results and Data Presented at AHS on Bokunebart for Headache Treatment Transcript
seekingalpha.comJun 5, 2026 · 4:22 PM
H. Lundbeck A/S (HLBBF) Shareholder/Analyst Call Transcript
H. Lundbeck A/S (HLBBF) Shareholder/Analyst Call Transcript
seekingalpha.comMar 18, 2026 · 12:02 PM
H. Lundbeck A/S (HLBBF) Q4 2025 Earnings Call Transcript
H. Lundbeck A/S (HLBBF) Q4 2025 Earnings Call Transcript
seekingalpha.comFeb 4, 2026 · 1:40 PM
H. Lundbeck Launches Bid for Avadel in Move to Scuttle Alkermes Deal
The unsolicited bid—worth up to $2.25 billion —potentially upends Avadel's deal to be acquired by Alkermes.
wsj.comNov 14, 2025 · 9:40 AM
H. Lundbeck A/S (HLBBF) Q3 2025 Earnings Call Transcript
H. Lundbeck A/S (OTCPK:HLBBF) Q3 2025 Earnings Call November 12, 2025 7:00 AM EST Company Participants Charl van Zyl - President & CEO Thomas Gibbs - Executive VP & Head of Lundbeck in United States Michala Fischer-Hansen - Executive VP and Head of Europe & International Markets Johan Luthman Maria Alfaiate - Executive Vice President of Corporate, Portfolio & Product Strategy Joerg Hornstein - CFO & Executive VP of Corporate Functions Conference Call Participants Charles Pitman - Barclays Bank PLC, Research Division Kirsty Ross-Stewart - BNP Paribas, Research Division Lucy-Emma Codrington-Bartlett - Jefferies LLC, Research Division Presentation Operator Ladies and gentlemen, welcome to the Lundbeck Financial Statement for the First 9 Months of 2025 Conference Call. I'm Lorenzo, the Chorus Call operator.
seekingalpha.comNov 12, 2025 · 7:11 PM
Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan
VALBY, Denmark , March 10, 2025 /PRNewswire/ -- The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA). H. Lundbeck A/S (Lundbeck) announced that amlenetug has received Orphan Drug Designation (ODD) from the MHLW in Japan.
prnewswire.comMar 10, 2025 · 4:23 AM

SEC Filings

No recent filings indexed.

Frequently Asked Questions About HLBBF

Where can I find news about HLBBF?: The latest headlines, third-party analysis, and SEC filings for H. Lundbeck A/S (HLBBF) are listed on this page. Headlines come from across the financial press; filings come directly from SEC EDGAR.
Where are HLBBF's SEC filings?: H. Lundbeck A/S (HLBBF)'s 10-K (annual report), 10-Q (quarterly report), 8-K (current report), and proxy filings are listed in the SEC Filings section on this page with direct links to the official EDGAR copies.
Where are HLBBF's earnings call transcripts?: Full earnings call transcripts for H. Lundbeck A/S (HLBBF) — prepared remarks plus speaker-by-speaker analyst Q&A — live on the Earnings tab, alongside the Earnings Reports section that links each quarter's press release and SEC report.

H. Lundbeck A/S

Frequently Asked Questions About HLBBF

H. Lundbeck A/S

H. Lundbeck A/S (HLBBF) Q2 2026 Earnings Call Transcript

H. Lundbeck A/S (HLBBF) Discusses PROCEED Trial Results and Data Presented at AHS on Bokunebart for Headache Treatment Transcript

H. Lundbeck A/S (HLBBF) Shareholder/Analyst Call Transcript

H. Lundbeck A/S (HLBBF) Q4 2025 Earnings Call Transcript

H. Lundbeck Launches Bid for Avadel in Move to Scuttle Alkermes Deal

H. Lundbeck A/S (HLBBF) Q3 2025 Earnings Call Transcript

Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan

Frequently Asked Questions About HLBBF

H. Lundbeck A/S (HLBBF) Q2 2026 Earnings Call Transcript

H. Lundbeck A/S (HLBBF) Discusses PROCEED Trial Results and Data Presented at AHS on Bokunebart for Headache Treatment Transcript

H. Lundbeck A/S (HLBBF) Shareholder/Analyst Call Transcript

H. Lundbeck A/S (HLBBF) Q4 2025 Earnings Call Transcript

H. Lundbeck Launches Bid for Avadel in Move to Scuttle Alkermes Deal

H. Lundbeck A/S (HLBBF) Q3 2025 Earnings Call Transcript

Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan